share_log

EF Hutton Reiterates Hold on GT Biopharma, Maintains $2 Price Target

Benzinga ·  Aug 7, 2023 12:31

EF Hutton analyst Tony Butler reiterates GT Biopharma (NASDAQ:GTBP) with a Hold and maintains $2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment